Study guide

15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium

Key Takeaways Explain This Topic AI

The Modified Aldrete Score evaluates 5 physiological domains (Activity, Respiration, Circulation, Consciousness, and Oxygen Saturation), each scored 0 to 2; a cumulative score of ≥9 is mandatory for discharge from Phase I PACU.

The simplified Apfel PONV risk score consists of 4 independent predictors (Female sex, Non-smoker status, History of PONV or motion sickness, and Postoperative opioid use); risk escalates from ~10% with 0 factors to ~80% with 4 factors.

Multimodal PONV prophylaxis targets distinct receptor systems: Ondansetron (5-HT3 antagonist, 4 mg at end of surgery), Dexamethasone (corticosteroid, 4-8 mg at induction), Droperidol (D2 antagonist, 0.625-1.25 mg), and Scopolamine (muscarinic antagonist patch preop).

Negative Pressure Pulmonary Edema (NPPE) is triggered by intense inspiratory effort against an obstructed airway (e.g., post-extubation laryngospasm), generating severe subatmospheric intrathoracic pressure (-50 to -100 cmH2O) that transudates fluid into alveoli; management includes airway clearance, 100% O2, PEEP, and gentle diuresis.

Emergence delirium is an acute, hyperactive, disoriented state occurring immediately upon waking (common in young children following Sevoflurane and young trauma patients), whereas Postoperative Cognitive Dysfunction (POCD) is a subtle, long-term cognitive deterioration persisting weeks to months postoperatively.

Last updated: August 2026

15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium

The transition of care from the operating room to the Post-Anesthesia Care Unit (PACU) represents a high-vulnerability phase in perioperative medicine. The CRNA must master objective discharge criteria, aggressive multimodal antiemetic strategies, rapid diagnosis of post-extubation respiratory failure, and the clinical distinction between acute emergence delirium and chronic postoperative cognitive decline.

1. PACU Organizational Phases & Fast-Tracking

Post-anesthesia care is divided into functional phases based on patient acuity and level of monitoring required: +---------------------------------------------------------------------------------------------------------+

  • | PACU FUNCTIONAL PHASES & DEFINITIONS |
  • +------------------+----------------------------------+---------------------------------------------------+
  • | Phase | Primary Clinical Focus | Key Staffing & Monitoring Standards |
  • +------------------+----------------------------------+---------------------------------------------------+
  • | **Phase I PACU** | • Acute emergence and recovery | • 1:1 or 1:2 nurse-to-patient ratio |
  • | | • Re-establishment of airway | • Continuous pulse oximetry, ECG, automated NIBP |
  • | | reflexes and hemodynamic stab. | • Readiness for transition to Phase II or floor |
  • +------------------+----------------------------------+---------------------------------------------------+
  • | **Phase II PACU**| • Step-down recovery preparing | • 1:3 to 1:5 nurse-to-patient ratio |
  • | | for discharge home / ward | • Focus on oral intake tolerance, ambulation, pain|
  • | | • Education of patient/caregiver | control, and voiding (when indicated) |
  • +------------------+----------------------------------+---------------------------------------------------+
  • | **Fast-Tracking**| • Bypassing Phase I PACU directly| • Utilizes short-acting anesthetics (TIVA, des- |
  • | | from the OR to Phase II PACU | flurane, remifentanil, regional techniques) |
  • | | • Reduces hospital costs & stay | • Requires meeting White-Song fast-track criteria |
  • +------------------+----------------------------------+---------------------------------------------------+
  • 2. Modified Aldrete Scoring System

The Modified Aldrete Score is the gold standard objective metric utilized globally to determine readiness for discharge from Phase I PACU. It evaluates 5 core domains , each graded from 0 to 2 points: +---------------------------------------------------------------------------------------------------------+

  • | MODIFIED ALDRETE SCORING CRITERIA |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | Clinical Domain | Evaluation Criteria | Score |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **1. Motor Activity** | • Moves 4 extremities voluntarily or on command | 2 |
  • | | • Moves 2 extremities voluntarily or on command | 1 |
  • | | • Unable to move extremities voluntarily or on command | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **2. Respiration** | • Able to breathe deeply and cough freely | 2 |
  • | | • Dyspneic, shallow, or limited breathing | 1 |
  • | | • Apneic | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **3. Circulation** | • Blood pressure within ± 20% of pre-anesthetic baseline | 2 |
  • | | • Blood pressure within ± 20% to 50% of pre-anesthetic baseline | 1 |
  • | | • Blood pressure within ± >50% of pre-anesthetic baseline | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **4. Consciousness** | • Fully awake, alert, and oriented | 2 |
  • | | • Arousable on calling (responds to verbal stimulation) | 1 |
  • | | • Completely unresponsive | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **5. Oxygen Saturation**| • SpO₂ > 92% on room air | 2 |
  • | | • Requires supplemental O₂ to maintain SpO₂ > 90% | 1 |
  • | | • SpO₂ < 90% with supplemental oxygen | 0 |

+-------------------------+---------------------------------------------------------------------+---------+ Discharge Threshold ≥ 9 / 10 ( with no individual score = 0 ) \text{Discharge Threshold} \ge 9 / 10 \quad (\text{with no individual score } = 0) Discharge Threshold ≥ 9/10 ( with no individual score = 0 )

Note on Post-Anesthesia Discharge Scoring System (PADSS) for Ambulatory Discharge: For Phase II discharge to home, the PADSS score evaluates vital signs, ambulation, nausea/vomiting, pain, and surgical bleeding (score ≥ 9 / 10 \ge 9/10 ≥ 9/10 required). Routine mandatory voiding and oral liquid intake are no longer required for all patients prior to discharge unless specifically indicated (e.g., spinal anesthesia, pelvic surgery, history of urinary retention).

3. Postoperative Nausea & Vomiting (PONV): Risk Stratification & Multimodal Prophylaxis

PONV occurs in 30 % 30\% 30% of unselected surgical patients and up to 70 − 80 % 70 - 80\% 70 − 80% of high-risk patients. It is the leading cause of unexpected hospital admission following ambulatory surgery.

  • The Simplified Apfel Risk Score +-------------------------------------------------------------------------+
  • | APFEL SIMPLIFIED PONV SCORE |
  • +------------------------------------+------------------------------------+
  • | The 4 Independent Risk Factors | Risk Factor Count & PONV Incidence |
  • +------------------------------------+------------------------------------+
  • | 1. **Female Gender** | • 0 Factors: ~10% risk |
  • | 2. **Non-Smoker Status** | • 1 Factor: ~20% risk |
  • | 3. **History of PONV or Motion Sickness** | • 2 Factors: ~40% risk |
  • | 4. **Postoperative Opioid Use** | • 3 Factors: ~60% risk |
  • | | • 4 Factors: ~80% (79%) risk |

+------------------------------------+------------------------------------+ [THE EMETIC PATHWAY & RECEPTOR TARGETS]

  • [Chemoreceptor Trigger Zone (CTZ)] <--- Area Postrema (Outside BBB)
  • Receptors: 5-HT₃, D₂, NK₁
  • |
  • v
  • [Vomiting Center / NTS (Medulla)] <--- Vestibular System (H₁, M₁)
  • Receptors: H₁, M₁, NK₁ GI Tract / Vagus (5-HT₃, NK₁)
  • |
  • v
  • [Motor Outflow: Phrenic / Vagal] ---> Diaphragm & Abdominal Wall Contraction
  • Multimodal Antiemetic Pharmacotherapy

Guidelines recommend administering 2 or more prophylactic antiemetics from different pharmacologic classes for patients with ≥ 2 \ge 2 ≥ 2 Apfel risk factors: +---------------------------------------------------------------------------------------------------------+

  • | MULTIMODAL PONV PROPHYLACTIC PHARMACOPEIA |
  • +---------------------+-------------------+---------------------+-----------------------------------------+
  • | Drug Class & Name | Standard Dose | Timing of Dose | Mechanism & Clinical Considerations |
  • +---------------------+-------------------+---------------------+-----------------------------------------+
  • | **5-HT₃ Antagonist**| 4 mg IV | **At conclusion of**| • Blocks 5-HT₃ receptors in CTZ & vagal |
  • | *Ondansetron* | | **surgery** | afferents; headache; QT prolongation |
  • +---------------------+-------------------+---------------------+-----------------------------------------+
  • | **Corticosteroid** | 4 - 8 mg IV | **At induction of** | • Centrally suppresses prostaglandin/ |
  • | *Dexamethasone* | | **anesthesia** | endorphin release; delayed onset (~2h)|
  • | | | | • Transient mild hyperglycemia |
  • +---------------------+-------------------+---------------------+-----------------------------------------+
  • | **D₂ Antagonist** | 0.625 - 1.25 mg IV| At conclusion of | • Subcortical D₂ receptor blockade |
  • | *Droperidol* | | surgery | • FDA black-box warning for QT interval |
  • | | | | • Extrapyramidal signs (avoid Parkinson)|
  • +---------------------+-------------------+---------------------+-----------------------------------------+
  • | **Anticholinergic** | 1.5 mg transdermal| Preoperatively | • Central muscarinic (M₁) receptor antag|
  • | *Scopolamine Patch* | patch | (or evening prior) | • Anisocoria/cycloplegia if eye contact |
  • | | | | • Dry mouth, urinary retention, sedation|
  • +---------------------+-------------------+---------------------+-----------------------------------------+
  • | **NK₁ Antagonist** | 40 mg PO | 1 - 2 hours preop | • Substance P inhibitor; exceptional for|
  • | *Aprepitant* | (or Fosaprepitant)| | preventing delayed (24-48h) emesis |
  • +---------------------+-------------------+---------------------+-----------------------------------------+
  • | **Propofol TIVA** | Infusion | Maintenance | • Eliminates volatile anesthetics & N₂O |
  • | | | | • Intrinsic D₂ and 5-HT₃ antagonism |
  • +---------------------+-------------------+---------------------+-----------------------------------------+
  • 4. PACU Respiratory Emergencies: Hypoxemia & Hypercapnia

Respiratory complications account for the highest proportion of early PACU critical events.

Differential Diagnosis & Management of PACU Hypoxemia

Atelectasis (Most Common Cause):

Mechanism: Loss of FRC, compression of lung bases, and absorption atelectasis from high intraoperative F i O 2 FiO_2 F i O 2 ​ .

Management: Upright positioning, deep breathing, incentive spirometry, continuous positive airway pressure (CPAP / PEEP).

Upper Airway Obstruction:

Mechanism: Pharyngeal soft tissue collapse (tongue falling back against posterior pharynx due to residual sedation/paralysis).

Management: Jaw thrust, head-tilt/chin-lift, lateral positioning, nasopharyngeal airway (trumpet) or oropharyngeal airway (if unresponsive).

Post-Extubation Laryngospasm:

Mechanism: Involuntary reflex spasm of laryngeal adductor muscles (true and false vocal cords) triggered by blood, secretions, or stimulation during light plane of anesthesia (Stage II).

Management Protocol:

Step 1: Remove offending stimulus; apply 100 % O 2 100\% \text{ O}_2 100% O 2 ​ with tight mask seal.

Step 2: Apply continuous positive pressure with bag-mask reservoir.

Step 3: Apply bilateral forceful pressure at Larson's notch (laryngospasm notch behind earlobe between mastoid process and ramus of mandible) with forward jaw thrust.

Step 4: If refractory, administer Succinylcholine 0.1 − 0.5 mg/kg 0.1 - 0.5 \text{ mg/kg} 0.1 − 0.5 mg/kg IV (subparalytic dose to break spasm while maintaining spontaneous ventilation) or full intubating dose ( 1.0 − 1.5 mg/kg 1.0 - 1.5 \text{ mg/kg} 1.0 − 1.5 mg/kg IV or 3 − 4 mg/kg 3 - 4 \text{ mg/kg} 3 − 4 mg/kg IM) with atropine if bradycardia occurs.

Negative Pressure Pulmonary Edema (NPPE / Type I):

Mechanism: Patient creates forceful, deep inspiratory efforts against a completely obstructed upper airway (e.g., severe laryngospasm, biting ETT). Generates extreme negative intrathoracic pressure ( − 50 to − 100 cmH 2 O -50 \text{ to } -100 \text{ cmH}_2\text{O} − 50 to − 100 cmH 2 ​ O ), massively increasing venous return, right ventricular preload, and pulmonary capillary hydrostatic pressure, precipitating rapid alveolar transudation.

Clinical Presentation: Pink, frothy sputum, tachypnea, coarse rales, severe arterial desaturation within minutes.

Treatment: Relieve obstruction, apply 100 % O 2 100\% \text{ O}_2 100% O 2 ​ , administer continuous positive airway pressure (CPAP) or re-intubate with PEEP ( 5 − 10 cmH 2 O 5 - 10 \text{ cmH}_2\text{O} 5 − 10 cmH 2 ​ O ), and provide supportive diuresis. [NEGATIVE PRESSURE PULMONARY EDEMA PATHWAY]

  • [Acute Upper Airway Obstruction (Laryngospasm)]
  • |
  • v
  • [Maximal Violent Inspiratory Effort by Patient]
  • |
  • v
  • [Extreme Negative Intrathoracic Pressure: -50 to -100 cmH₂O]
  • |
  • v
  • [Massive Increase in Venous Return & Pulmonary Capillary Hydrostatic P]
  • |
  • v
  • [Alveolar-Capillary Membrane Disruption & Fluid Transudation]
  • |
  • v
  • **[Pink Frothy Secretions, Severe Hypoxemia, Flash Edema]**
  • Causes of PACU Hypercapnia & Hypoventilation

Residual Neuromuscular Blockade: Train-of-four (TOF) ratio < 0.9 <0.9 < 0.9 causes airway collapse, impaired swallowing, aspiration risk, and hypoventilation. Standard of care requires quantitative neuromuscular monitoring and reversal with Sugammadex or Neostigmine + Glycopyrrolate .

Opioid-Induced Respiratory Depression: Characterized by slow, deep, regular respirations with pinpoint pupils and hypercapnia. Treat by carefully titrating Naloxone 0.04 − 0.08 mg 0.04 - 0.08 \text{ mg} 0.04 − 0.08 mg IV increments every 2-3 minutes to restore spontaneous ventilation without precipitating acute withdrawal, catecholamine surge, hypertension, and flash pulmonary edema.

5. Emergence Delirium vs Postoperative Cognitive Dysfunction (POCD) +---------------------------------------------------------------------------------------------------------+

  • | EMERGENCE DELIRIUM vs POSTOPERATIVE COGNITIVE DYSFUNCTION |
  • +------------------------+------------------------------------+-------------------------------------------+
  • | Feature | Emergence Delirium / Agitation | Postoperative Cognitive Dysfunction (POCD)|
  • +------------------------+------------------------------------+-------------------------------------------+
  • | **Onset & Timing** | Immediate: upon awakening in PACU | Delayed: manifests weeks to months postop |
  • | **Duration** | Transient: typically 15 - 45 min | Prolonged: weeks, months, or permanent |
  • | **Clinical Picture** | Violent motor agitation, thrashing,| Subtle memory loss, executive dysfunction,|
  • | | crying, combativeness, confusion | personality change, inability to multi-tsk|
  • | **Risk Populations** | Children (2-6 yr) with Sevoflurane;| Elderly (>65 yr), lower baseline education|
  • | | young athletic males, PTSD/trauma | major cardiac/orthopedic surgery, ICU stay|
  • | **Initial Management** | 1. Rule out hypoxemia/hypercapnia | Neuropsychometric baseline testing; multi-|
  • | | 2. Treat full bladder / pain | multimodal anesthetic depth optimization |
  • | | 3. Low-dose Dexmedetomidine/Propofol| (avoid excessive burst suppression) |
  • +------------------------+------------------------------------+-------------------------------------------+

Loading diagram... PACU Post-Extubation Airway Complication Algorithm